TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors
Clinical trial NCT03387917 · TERMINATED
Trial details
- NCT number
- NCT03387917
- Sponsor
- Swiss Cancer Institute
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-12
- Primary completion
- 2023-09-22
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.